NMPA will Further Strengthen the ADR Monitoring and Evaluation System
On July 30, 2020, NMPA released a notice about further strengthening the ADR (Adverse Drug Reaction) monitoring and evaluation system (the ADR monitoring and evaluation herein includes adverse drug reactions, medical device adverse events, cosmetic adverse reactions, drug abuse monitoring and evaluation). NMPA has set major goals, clarified significant tasks and provided supporting measures of governments to the local NMPAs.
